Pro-Dex, Inc. Announces Fiscal 2023 First Quarter Results

Rhea-AI Summary

Pro-Dex, Inc. (NASDAQ:PDEX) reported a Q1 fiscal 2023 net sales increase to $11.1 million, up 11% from $10.0 million in Q1 fiscal 2022. This growth was attributed to a $0.8 million rise in surgical handpiece repairs and a $0.7 million boost in NRE and prototype sales. However, medical device sales dipped by $397,000. The gross profit fell by 14% to $2.99 million, yielding a gross margin decrease to 27%. Net income remained stable at $1.1 million, with earnings per diluted share rising to $0.29. The FDA has authorized manufacturing at the Franklin facility, and negotiations with the largest customer are expected to yield further revenue.

Positive

• Net sales increased by 11%, reaching $11.1 million.
• Stable net income at $1.1 million, with EPS rising to $0.29.
• FDA authorization for manufacturing at the Franklin facility.
• Ongoing negotiations with largest customer may bring additional revenue.

Negative

• Gross profit decreased by 14%, down to $2.99 million.
• Gross margin declined by 7 percentage points to 27%.
• Medical device sales fell by $397,000 compared to Q1 fiscal 2022.

IRVINE, CA / ACCESSWIRE / November 3, 2022 / PRO-DEX, INC. (NASDAQ:PDEX) today announced financial results for its fiscal 2023 first quarter ended September 30, 2022. The Company also filed its Quarterly Report on Form 10-Q for the first quarter of fiscal year 2023 with the Securities and Exchange Commission today.

Net sales for the three months ended September 30, 2022 increased $1.1 million, or 11%, to $11.1 million from $10.0 million for the three months ended September 30, 2021. The increase is driven primarily by $0.8 million in increased repairs of the surgical handpiece we sell to our largest customer as well as increases of $0.7 million in sales of our NRE & proto-type offerings. Offsetting these increases, sales of our medical devices decreased approximately $397,000 in the first quarter of fiscal 2023 compared to the corresponding period of the prior fiscal year. As previously described, sales are often not on a continuous upward trajectory due to variability in new product launches and customer planned inventory builds, but we remain confident in our continued long-term sales growth.

Gross profit for the three months ended September 30, 2022, decreased $472,000, or 14%, compared to the year-ago period. Gross margin decreased by 7 percentage points to 27% during the three months ended September 30, 2022, compared to 34% during the corresponding year-ago period, due primarily to repairs of the surgical handpiece we sell to our largest customer. Beginning in fiscal 2023 we began upgrading all repaired units for this customer to the newest release of the handpiece at no additional cost. We have continued to deliver these upgrades in good faith, while continuing negotiations with this customer to compensate us for these more costly upgrades.

Operating expenses (which include selling, general and administrative, and research and development expenses) for the quarter ended September 30, 2022 decreased $104,000 from the corresponding year-ago period. The decrease resulted from decreased non-cash stock compensation expense related to previously issued awards as well as reduced research and development expenses as we have more billable projects in the first quarter of fiscal 2023 compared to the corresponding period of the prior fiscal year.

Net income for the quarter ended September 30, 2022 was $1.1 million, or $0.29 per diluted share, compared to $1.1 million, or $0.28 per diluted share, for the quarter ended September 30, 2021.

CEO Comments
Richard L. ("Rick") Van Kirk, the Company's President and Chief Executive Officer, commented, "We are pleased with our first quarter results and to share that the FDA has authorized commencement of manufacturing activities at the Franklin facility. Additionally," concluded Mr. Van Kirk, "we are confident that our negotiations with our largest customer related to upgrades will conclude with an infusion of additional revenue."

About Pro-Dex, Inc.:
Pro-Dex, Inc. specializes in the design, development, and manufacture of autoclavable, battery-powered and electric, multi-function surgical drivers and shavers used primarily in the orthopedic, thoracic, and maxocranial facial markets. We have patented adoptive torque-limiting software and proprietary sealing solutions that appeal to our customers, primarily medical device distributors. Pro-Dex also sells compact pneumatic air motors for a variety of industrial applications. Pro-Dex's products are found in hospitals and medical engineering labs around the world. For more information, visit the Company's website at www.pro-dex.com.

Statements herein concerning the Company's plans, growth, and strategies may include 'forward-looking statements' within the context of the federal securities laws. Statements regarding the Company's future events, developments, and future performance, as well as management's expectations, beliefs, plans, estimates or projections relating to the future, are forward-looking statements within the meaning of these laws. The Company's actual results may differ materially from those suggested as a result of various factors. Interested parties should refer to the risk factors and other disclosures concerning the operational and business concerns of the Company set forth in the Company's filings with the Securities and Exchange Commission.

(tables follow)

PRO-DEX, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)
(In thousands, except share amounts)

		September 30, 2022				June 30, 2022
ASSETS
Current Assets:
Cash and cash equivalents..........................................		$	2,798			$	849
Investments.................................................................			813				755
Accounts receivable, net of allowance for doubtful accounts of $2 and $0 at September 30, 2022 and at June 30, 2022, respectively.................................			11,045				15,384
Deferred costs...........................................................			587				710
Inventory....................................................................			15,664				12,678
Prepaid expenses and other current assets.................			928				790
Total current assets.................................................			31,835				31,166
Land and building, net...................................................			6,319				6,343
Equipment and leasehold improvements, net................			4,852				4,833
Right of use asset, net....................................................			2,156				2,248
Intangibles, net...............................................................			108				118
Deferred income taxes, net.............................................			764				797
Investments....................................................................			1,889				1,779
Other assets....................................................................			42				42
Total assets.................................................................		$	47,965			$	47,326
LIABILITIES AND SHAREHOLDERS' EQUITY
Current Liabilities:
Accounts payable........................................................		$	3,549			$	3,761
Accrued liabilities.......................................................			3,245				2,751
Income taxes payable.................................................			731				544
Deferred revenue........................................................			851				1,013
Note payable...............................................................			3,297				3,285
Total current liabilities............................................			11,673				11,354
Lease liability, net of current portion............................			1,954				2,054
Notes payable, net of current portion............................			9,922				10,250
Total non-current liabilities.....................................			11,876				12,304
Total liabilities............................................................			23,549				23,658
Shareholders' Equity:
Common stock; no par value; 50,000,000 shares authorized; 3,606,422 and 3,596,131 shares issued and outstanding at September 30, 2022 and June 30, 2022, respectively.............................................			7,354				7,682
Retained earnings.......................................................			17,062				15,986
Total shareholders' equity.......................................			24,416				23,668
Total liabilities and shareholders' equity............		$	47,965			$	47,326

PRO-DEX, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(Unaudited)
(In thousands, except share and per share amounts)

		Three Months Ended September 30,
		2022				2021
Net sales...........................................................................................................		$	11,087			$	9,988
Cost of sales.....................................................................................................			8,131				6,560
Gross profit.......................................................................................................			2,956				3,428
Operating expenses:
Selling expenses..........................................................................................			53				37
General and administrative expenses.........................................................			1,024				1,093
Research and development costs................................................................			929				980
Total operating expenses.................................................................................			2,006				2,110
Operating income.............................................................................................			950				1,318
Other income (expense):
Interest and dividend income......................................................................			218				24
Realized gain on sale of marketable equity investments..........................			6				-
Unrealized gain on marketable equity investments..................................			250				149
Interest expense...........................................................................................			(130	)			(120	)
Total other income...........................................................................................			344				53
Income before income taxes...........................................................................			1,294				1,371
Provision for income taxes..............................................................................			218				307
Net income..................................................................................		$	1,076			$	1,064
Basic and diluted net income per share:
Basic net income per share..............................................................................		$	0.30			$	0.29
Diluted net income per share..........................................................................		$	0.29			$	0.28
Weighted average common shares outstanding:
Basic....................................................................................................			3,616,392				3,651,334
Diluted.................................................................................................			3,694,959				3,777,118
Common shares outstanding ..........................................................................			3,606,422				3,666,319

CONTACT:
Richard L. Van Kirk, Chief Executive Officer
(949) 769-3200

SOURCE: Pro-Dex, Inc.

View source version on accesswire.com:
https://www.accesswire.com/723212/Pro-Dex-Inc-Announces-Fiscal-2023-First-Quarter-Results

FAQ

What were Pro-Dex's Q1 fiscal 2023 earnings results?

Pro-Dex reported net sales of $11.1 million and net income of $1.1 million, or $0.29 per diluted share.

How did Pro-Dex's sales perform compared to the previous year?

Sales increased by 11% from $10.0 million in Q1 fiscal 2022.

What challenges did Pro-Dex face in this quarter?

The company experienced a decline in medical device sales and a reduction in gross margin due to increased repair costs.

What is the outlook for Pro-Dex following the Q1 results?

Management is optimistic about upcoming revenue from negotiations with their largest customer.